Grifols, S.A.
GRFS Healthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow GRFS
Grifols, S.A. (GRFS) EV/Sales
As of 16 October 2026, Grifols, S.A. (GRFS) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 1.2× (March 2023) to 4.9× (January 2018); the current reading is higher than 15% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (8.86%) |
| FY2024 | 2.1× | 57.37% |
| FY2023 | 1.3× | 4.94% |
| FY2022 | 1.3× | (26.71%) |
| FY2022 | 1.7× | 0.82% |
| FY2021 | 1.7× | (48.85%) |
| FY2021 | 3.4× | 1.71% |
| FY2020 | 3.3× | (15.30%) |
| FY2020 | 3.9× | 1.01% |
| FY2019 | 3.9× | 0.19% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.8× | (3.76%) |
| Dec 2025 | 1.9× | (9.03%) |
| Sep 2025 | 2.1× | 3.17% |
| Jun 2025 | 2.0× | 2.42% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC compare | −0.3× |
| NSRX Nasus Pharma Ltd. compare | n/m |
| GRFS Grifols, S.A. | 1.8× |
| OGN Organon & Co. compare | 1.8× |
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.7× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| NVO Novo Nordisk A/S compare | 3.6× |
| BIIB Biogen Inc. compare | 4.0× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)